STOCK TITAN

Harmony Biosciences officer plans 1,800-share sale

An officer of Harmony Biosciences filed a Rule 144 notice to sell 1,800 shares after exercising stock options, disclosing additional recent 10b5-1 sales.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. (HRMY) has an officer, Kumar Budur, filing a notice of proposed sale of restricted or control securities under Rule 144. The filing covers up to 1,800 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on September 16, 2026, in connection with a cash exercise of stock options.

The filing also lists prior Rule 10b5-1 sales of common stock by Kumar Budur during the preceding three months, including separate transactions of 5,500 shares, 22,954 shares, and 5,500 shares on September 8 and September 4, 2026, respectively, with stated aggregate sale proceeds for each transaction.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 1,800 shares Common stock covered by Rule 144 notice for September 16, 2026 sale
Aggregate market value of proposed sale $75,906.00 Estimated for 1,800 Harmony Biosciences common shares to be sold
10b5-1 sale on September 8, 2026 (first transaction) 5,500 shares; $232,908.65 Rule 10b5-1 sale of Harmony Biosciences common stock
10b5-1 sale on September 8, 2026 (second transaction) 22,954 shares; $989,349.63 Rule 10b5-1 sale of Harmony Biosciences common stock
10b5-1 sale on September 4, 2026 5,500 shares; $230,911.45 Rule 10b5-1 sale of Harmony Biosciences common stock
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
10b5-1 regulatory
"10b5-1 Sales for KUMAR BUDUR 630 W Germantown Pike..."
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Exercise of Stock Options financial
"Common | 09/16/2026 | Exercise of Stock Options | Issuer |"
aggregate market value financial
"Common | Morgan Stanley Smith Barney LLC... | 1800 | 75906.00 |"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Harmony Biosciences (HRMY) by Kumar Budur report?

It reports a proposed Rule 144 sale by officer Kumar Budur of up to 1,800 shares of Harmony Biosciences common stock, expected on September 16, 2026, in connection with a cash exercise of stock options through Morgan Stanley Smith Barney LLC.

How many Harmony Biosciences (HRMY) shares are proposed to be sold under this Form 144?

The filing covers a proposed sale of 1,800 shares of Harmony Biosciences common stock, with an aggregate market value stated as $75,906.00, to be sold via Morgan Stanley Smith Barney LLC on September 16, 2026.

What recent 10b5-1 sales by Kumar Budur in HRMY stock are disclosed?

The notice lists three Rule 10b5-1 sales of Harmony Biosciences common stock: 5,500 shares for $232,908.65 and 22,954 shares for $989,349.63 on September 8, 2026, and 5,500 shares for $230,911.45 on September 4, 2026.

How will the shares in the new Harmony Biosciences (HRMY) sale be acquired?

The 1,800 shares covered by the notice are to be acquired via an exercise of stock options from the issuer, Harmony Biosciences Holdings, Inc., on September 16, 2026, with the exercise price to be paid in cash.

Which broker is handling the proposed Rule 144 sale for Harmony Biosciences (HRMY)?

The proposed sale of 1,800 Harmony Biosciences common shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, with the shares listed on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading